GSK Shares Traded Sideways Despite the Positive DREAM-7 Results

The GSK plc (LON: GSK) share price traded sideways despite announcing positive headline results from its DREAMM-7 head-to-head phase III clinical trial, underscoring the potential breakthrough in treating relapsed or refractory multiple myeloma.

This pivotal trial assessed the efficacy of belantamab mafodotin, a novel therapeutic approach, as a second-line treatment for this challenging haematological malignancy. The results from this interim analysis have sparked considerable excitement within the medical and scientific communities.

The DREAMM-7 trial aimed to address a pressing need for improved treatment options for patients grappling with relapsed or refractory multiple myeloma, a condition characterised by the uncontrolled proliferation of plasma cells in the bone marrow. 

Historically, daratumumab plus bortezomib and dexamethasone (BorDex) have been the established standard of care for these patients. However, the trial results have introduced a new ray of hope by showcasing the remarkable potential of belantamab mafodotin when administered in conjunction with BorDex.

One of the most compelling findings from the DREAMM-7 trial is the statistically significant improvement in progression-free survival (PFS) achieved by the belantamab mafodotin and BorDex combination compared to the daratumumab plus BorDex regimen.

This outcome underscores the potential of belantamab mafodotin to extend the time patients can live without their disease advancing or experiencing severe complications, offering them a significantly improved quality of life.

Additionally, the trial has shed light on a noteworthy trend in overall survival (OS). The data shows a strong and clinically meaningful OS trend, as indicated by the nominal p-value of less than 0.0005. 

The finding has generated optimism among clinicians and researchers, suggesting that belantamab mafodotin may not only delay disease progression but also enhance patients' chances of long-term survival. It's important to emphasise that the trial is ongoing, with further follow-up data on overall survival pending.

Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D, GSK, said: “Patients with multiple myeloma need treatment options after first relapse that are efficacious, readily accessible and have novel mechanisms of action. We are particularly encouraged by the potential for belantamab mafodotin when combined with BorDex to address the high unmet need in relapsed/refractory multiple myeloma, given the head-to-head comparison with the daratumumab-based standard of care regimen.”

GSK share price. 

The GSK share price traded sideways despite the positive results from the DREAMM-7 phase III trial.